Becton, Dickinson and Company (NYSE:BDX) reported higher fiscal fourth-quarter revenue and adjusted earnings as demand for patient monitoring, biologic drug delivery and other products helped offset a difficult comparison for its Alaris infusion platform. The medical technology company said fourth-quarter revenue rose 5.6% to $5.3 billion, while adjusted diluted earnings per share increased 27.3% to […]

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its competitors? We will compare Becton, Dickinson and Company to related companies based on the strength of its dividends, profitability, risk, institutional ownership, analyst recommendations, earnings and […]